Bahce et al. [111] conducted a pilot study using 89Zr-bevacizumab PET imaging in patients with advanced non-small cell lung cancer (NSCLC) to evaluate VEGF-A expression. Here, VEGFA is linked to non-small cell lung carcinoma.